Stocks of Capricor Therapeutics Inc (NASDAQ:CAPR) traded higher last session on Wall Street, up 8.26% to $11.94.
CAPR stock price is now 0.03 away from the 50-day moving average and May 13 AMC away from the 200-day moving average. The market capitalization of the company currently stands at $377.55M.
With the price target of $31, Roth Capital recently initiated with Buy rating for Capricor Therapeutics Inc (NASDAQ: CAPR). On October 21, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $35, while ‘Oppenheimer’ rates the stock as ‘Outperform’
In other news, Nippon Shinyaku Co Ltd, 10% Owner bought 2,798,507 shares of the company’s stock on Sep 20 ’24. The stock was bought for $14,999,998 at an average price of $5.36. Upon completion of the transaction, the 10% Owner now directly owns 7,090,351 shares in the company, valued at $84.66 million. A total of 12.16% of the company’s stock is owned by insiders.
During the past 12 months, Capricor Therapeutics Inc has had a low of $3.52 and a high of $23.40. The fifty day moving average price for CAPR is $10.825 and a two-hundred day moving average price translates $13.37315 for the stock.
The latest earnings results from Capricor Therapeutics Inc (NASDAQ: CAPR) was released for 2025-03-31. The net profit margin was -317.13% and return on equity was -75.39% for CAPR.
